Страна: Армения
Език: английски
Източник: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
streptomycin (streptomycin sulfate)
LABORATORIO REIG JOFRE
J01GA01
streptomycin (streptomycin sulfate)
1000mg
powder for solution for injection
(100) glass vial 10ml
Prescription
Registered
2016-08-09
SUMMARY OF PRODUCT CHARACTERISTICS 1. N AME OF THE MEDICINAL PRODUCT _ _ Reig Jofré streptomycin sulphate 1 g powder and solvent for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains: - Streptomycin (sulphate) 1g - Excipients: See section 6.1 for full list of excipients. 3. PHARMACEUTICAL FORM Powder and solvent for solution for injection. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Reig Jofre streptomycin sulphate is indicated for treating the infections listed below in adults and children : - Tuberculosis in all its forms (in conjunction with other tuberculostatics) - Brucelosis - Plague disease (infectious) - Endocarditis caused by viridans group streptococci o r _S. faecalis _ (in conjunction with penicillin) - Urinary tract infections - Gonorrhea 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Adults_ _ _ 1 g per day, which can be administered in two equal doses, 1 every 12 hours _Children_ _ _ _ _ 0.5 g per day, which can be administered in two equal doses, 1 every 12 hours Children may be administered 20-40 mg/kg/day, in 2-4 doses, 1 every 6-12 hours. _Elderly patients_ _ _ 0.5g -1.5 g per day. Maximum dose: 2 g per day. _Patients with impaired renal function_ _ _ Adjust dose according to creatinine clearance. Route of administration Streptomycin sulphate is administered via intramuscular injection. 4.3 CONTRA - INDICA TIONS Hypersensitivity to the active ingredient or to aminoglycosides in general , since there is evidence of crossover allergy between them. 4.4 WARNINGS AND SPECIFIC PRECAUTIONS FOR USE - Streptomycin is neurotoxi c and can affect cranial nerve VIII (particularly its vestibular branch) , causing nausea, vomiting, vertigo and deafness . The incidence of these adverse effects, more pronounced in elderly patients and patients with impaired renal function , is proportional to t r e a t m e n t d u r a t i o n a n d t o t a l d o s e administered . Hearing a n d b a l a n c e f u n c t i o n s m u s t be monitored in patients undergoing prolonged periods Прочетете целия документ